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Abstract 
Background: Kidney cancer is often asymptomatic, leading to proposals for a screening programme. The views of 
the public towards introducing a new screening programme for kidney cancer are unknown. The aim of this study 
was to explore attitudes towards kidney cancer screening and factors influencing intention to attend a future screen‑
ing programme.
Methods: We conducted an online population‑based survey of 1021 adults aged 45–77 years. The main outcome 
measure was intention to attend four possible screening tests (urine, blood, ultrasound scan, low‑dose CT) as well as 
extended low‑dose CT scans within lung cancer screening programmes. We used multivariable regression to examine 
the association between intention and each screening test.
Results: Most participants stated that they would be ‘very likely’ or ‘likely’ to undergo each of the screening tests 
[urine test: n = 961 (94.1%); blood test: n = 922 (90.3%); ultrasound: n = 914 (89.5%); low‑dose CT: n = 804 (78.8%); 
lung CT: n = 962 (95.2%)]. Greater intention to attend was associated with higher general cancer worry and less 
perceived burden/inconvenience about the screening tests. Less worry about the screening test was also associated 
with higher intention to attend, but only in those with low general cancer worry (cancer worry scale ≤ 5). Compared 
with intention to take up screening with a urine test, participants were half as likely to report that they intended to 
undergo blood [OR 0.56 (0.43–0.73)] or ultrasound [OR 0.50 (0.38–0.67)] testing, and half as likely again to report that 
they intended to take part in a screening programme featuring a low dose CT scan for kidney cancer screening alone 
[OR 0.19 (0.14–0.27)].
Conclusion: Participants in this study expressed high levels of intention to accept an invitation to screening for kid‑
ney cancer, both within a kidney cancer specific screening programme and in conjunction with lung cancer screen‑
ing. The choice of screening test is likely to influence uptake. Together these findings support on‑going research into 
kidney cancer screening tests and the potential for combining kidney cancer screening with existing or new screen‑
ing programmes.
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Background
Internationally, there is great interest in evaluating the 
potential for a screening programme for kidney can-
cer [1–3]. Half of all patients with kidney cancer have 
asymptomatic disease and up to a quarter of individu-
als have evidence of metastases at diagnosis [4]. Survival 
is strongly related to stage at diagnosis [4]. A screening 
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programme, potentially in a selected higher risk popula-
tion, may down-stage the disease, reduce the prevalence 
of metastatic tumours at diagnosis, improve survival and 
decrease the expenditure related to systemic therapies 
[5].
The two currently available potential screening modali-
ties are ultrasound and CT scan. Our group reported a 
detailed cost-effectiveness analysis of ultrasound scan-
based screening. This suggested that screening may 
have acceptable cost-effectiveness in men aged 50–60y 
(£18–22k/QALY) and in women aged 60 if the prevalence 
of kidney cancer is at least 0.2% [6]. When combined 
with other CT scan-based screening programmes, such 
as current lung cancer screening pilots [7], additional 
screening for kidney cancer by CT scan has the poten-
tial to provide health and economic benefits. Research 
into new urinary (i.e. perilipin 1 and aquaporin 2 [8]) and 
blood based markers (i.e. KIM-1 [9]) is also on-going and 
these may provide additional options for screening in the 
future.
Whichever screening modality is used, the benefits will 
only be realised if sufficient numbers of the target popu-
lation undergo screening. This requires consideration 
of the views of the population on the acceptability and 
potential engagement with future programmes [10]. To 
our knowledge, no studies have addressed these issues for 
kidney cancer. We aimed to explore the attitudes of the 
public towards potential future screening programmes 
for kidney cancer with different tests and to understand 
the individual and system-level factors influencing inten-
tion to take up screening.
Methods
Study design
We conducted an online population-based survey. The 
survey was conducted and is reported in line with the 
checklist for Reporting Results of Internet E-Surveys 
(CHERRIES) [11].
Participants and recruitment
We aimed to recruit 1000 participants (50% female) 
through Prolific (www.proli fic.ac), an online platform in 
which individuals volunteer to take part in studies and 
are compensated for their time at an hourly rate (£6/
hour). Participants were eligible if they were between 
45–79 years of age and, in line with accepted practice 
[12], had a Prolific approval rating ≥ 95%. The approval 
rating reflects the percentage of studies that participants 
have completed that have been approved by researchers. 
We chose the age range 45–79 years because it is unlikely 
that a future kidney cancer screening programme would 
screen individuals younger than 45 and we wanted to 
be able to capture any differences in attitudes in older 
groups. We did not prevent participants with a history of 
kidney cancer from completing the survey but their data 
were subsequently excluded from the analysis.
When the survey was launched, a random subset of 
eligible participants were invited to complete the survey 
via email through the Prolific platform (Additional file 1). 
The survey then remained open to new participants until 
recruitment was complete. After starting the survey, all 
participants had the option to ‘return’ their submission 
at any point. This allowed them to stop part way through 
the study without affecting their Prolific rating. Data 
from participants who returned their submission were 
deleted and not analysed. Cookies were not used to iden-
tify each participant computer. Duplicate entries were 
prevented within the Prolific platform through use of 
unique participant identification numbers.
Survey
The survey was developed by the study team and piloted 
with two patient and public representatives to check 
that the questions were comprehensible and being inter-
preted correctly. Validated questions were used wherever 
possible. A complete version of the survey is provided 
in Additional file  2. Briefly, participants first provided 
socio-demographic details including age, lifestyle, highest 
level of education, employment and socioeconomic sta-
tus (assessed via the occupation of the household’s chief 
income earner [13, 14]). They were then asked questions 
about their medical screening history, perception of can-
cer risk, cancer worry [15], knowledge of kidney cancer 
symptoms and risk factors for kidney cancer [16]. Partici-
pants were then given brief summary information about 
kidney cancer and the estimated benefits and harms of 
four potential screening methods using data from the lit-
erature [5]. A series of questions followed about beliefs 
and attitudes concerning kidney cancer and screening 
[17] and whether, based on the information provided, 
participants would take part in screening. Finally, par-
ticipants were asked about how much influence various 
other factors, identified from the literature [18], would 
have on their decision to undergo screening. Writ-
ten online consent was obtained from each participant 
before they began the survey.
Data collection
The questions and scenarios were embedded within an 
online questionnaire and two studies (one for men and 
one for women) run in parallel on the Prolific website 
to enable us to achieve a sample with equal numbers of 
men and women. All questions except those inviting free 
text responses were mandatory for all participants. The 
questions were distributed over 22 pages with between 
one and seven questions per page to enable completion 
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on tablets or smartphones with small screens. It was not 
possible for participants to go back through the pages 
and change their answers. The technical functionality 
of the electronic questionnaire was tested by the study 
team. We included an instructional manipulation check 
to identify inattentive participants and increase the valid-
ity and reliability of the responses [19]. Participants who 
failed to answer this question correctly were excluded 
from the study.
Analysis
We used descriptive statistics to characterise the partici-
pants and their overall attitudes towards, and intention to 
take-up, kidney cancer screening. Socioeconomic status 
(SES) was classified as higher (ABC1) and lower (C2DE). 
For awareness of kidney cancer symptoms and risk fac-
tors participants were categorised into two groups (high/
low) based on whether their overall score was above or 
below the median (see Additional file 2 for details).
We used a linear regression model to analyse differ-
ences between the burden/ inconvenience and worry 
associated with each screening test. The null hypothesis 
of no difference between the four groups was tested using 
an F-test, followed by the estimation of four pairwise 
contrasts between the screening tests: (1) urine vs blood; 
(2) urine vs ultrasound; (3) urine versus CT; and (4) ultra-
sound vs CT. Confidence intervals (98.75%, based on a 
Bonferroni corrected significance threshold of 1.25%) 
are presented for these analyses to acknowledge that four 
pairwise comparisons were performed.
Logistic regression was then used to examine the influ-
ence of the different screening tests and participant char-
acteristics on intention to take up screening. For these 
analyses, cancer beliefs about treatment was treated as a 
continuous variable from 1–5, 1 reflecting the view that 
most cancer treatment is worse than the cancer itself. 
Cancer beliefs about outcomes was similarly treated as a 
continuous variable, computed by combining responses 
from the relevant questions 1, 4 and 6 using published 
coefficients [17] (see Additional file 2 for details).
To enable us to compare the intention to take up 
each of the five screening test modalities, we included 
the screening test as an independent variable as well as 
adjusting for participant characteristics (age, sex, educa-
tion level, ethnicity, self-reported general health, coun-
try of residence, income group, body mass index (BMI), 
smoking status, prior history of cancer, family history of 
kidney cancer), cancer worry, perceived risk of cancer, 
beliefs about cancer outcomes and treatments, the mean 
burden/inconvenience and the mean worry associated 
with all of the tests combined for each participant. The 
analysis was adjusted for the clustering of responses by 
participant using the—cluster—command in Stata.To 
enable comparison of participant characteristics associ-
ated with intention to take up each of the screening tests 
separately, we repeated the analysis for each screening 
test with the burden/inconvenience and worry associ-
ated with each specific test. We checked for collinear-
ity between the covariates in the regression models by 
calculating the variance inflation factors (vif ) for each 
covariate using the command –collin- in Stata. All vari-
ables had vif values less than 4.20, suggesting no evidence 
of substantial collinearity. We also separately assessed 
for interactions between cancer worry, perceived risk of 
cancer and beliefs about cancer outcomes, and burden/
inconvenience of the screening tests and worry about 
the screening tests by adding interaction terms into the 
regression. The hypothesis being tested was that worry 
about the screening tests and the perceived burden/
inconvenience of screening may have less of an impact on 
intention to take up screening among those individuals 
with higher cancer worry, higher perceived risk of cancer 
or stronger negative beliefs about the outcomes of cancer. 
Interactions were considered significant if p<0.05. Where 
the interaction was significant we additionally stratified 
by high (> 5) and low (≤ 5) cancer worry and estimated 
the association between worry about screening tests and 
intention to take up screening separately in these two 
groups. All results from these analyses are presented as 
odds ratios (OR) with 95% confidence intervals.
All analyses were performed using Stata Version 14.
Patient and public involvement
Two members of the public contributed, through face-
to-face discussions and email, to the development of 
the survey and participant information sheet. They also 
provided comments on the final manuscript prior to 
submission.
Results
At the time of recruitment, 7767 participants were reg-
istered with Prolific and met the eligibility criteria for 
the study. Based on demographic data on the Prolific 
website, approximately 80% of these were White/Cau-
casian, 34% male, 53% lived in the UK, 33% lived in the 
US, 15% were current smokers and 43% had a university 
level education. 51% considered themselves to be in the 
top five deciles of socioeconomic status. The survey was 
live for eight hours. During this time 1190 participants 
clicked through to view the participant information leaf-
let and consent form. 1077 (90.5%) started the survey. 
29 failed the instructional manipulation check and so 
were excluded. A further 22 returned their submission. 
1025 (86%) completed the survey. Four of those 1025 
participants reported a history of kidney cancer and so 
were excluded from analysis. The characteristics of the 
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remaining 1021 participants are shown in Table  1.Par-
ticipants were aged from 45–77 years, 513 (50.2%) were 
female. Reflecting the eligible participant pool, the major-
ity were from the UK (668, 65.4%) or USA (183, 17.9%), 
46% had a university level education and 16.1% were 
current smokers. Men were over-represented amongst 
the study participants due to our sex-specific recruit-
ment strategy. The proportion of participants of White 
ethnicity (95.3%) and those of higher SES (76.2%) were 
also higher among the study participants than the eligi-
ble population. A previous diagnosis of any cancer was 
reported by 63 (6.2%) and a family history of kidney can-
cer by 29 (2.8%). The majority (835, 81.8%) knew nothing 
about kidney cancer or had only heard of the condition 
before participating in the survey.
Cancer beliefs and attitudes towards kidney cancer 
screening
Table  2 shows the participants’ general cancer beliefs 
and their attitudes towards kidney cancer screening. 
The majority of participants were positive about cancer 
outcomes, only 6.7% expressed cancer fatalism. Atti-
tudes towards screening were also positive, the majority 
(91.8%) agreed with the statement that screening could 
reduce the chance of dying from kidney cancer.
Intention to attend screening
Intention to take-up screening was high overall (Table 3), 
with over 90% reporting that they would accept the invi-
tation for screening by urine testing, blood testing or 
low-dose CT combined with lung screening. Intention 
was lower for ultrasound (89.5%) and low-dose CT of 
kidneys alone (78.8%).
Fig.  1 shows the pattern of responses at an individual 
level across the five modalities. A majority (771, 76%) 
reported that they would attend screening by all five 
modalities, 20 (2%) said they would not attend screening 
by any method and 28 (27%) reported they would only 
attend screening by the combined lung and kidney CT 
scan and not by the other methods. 217 (21%) partici-
pants would not attend screening by CT scan of the kid-
neys alone, but 181 of these 217 (83%) participants would 
attend kidney cancer screening by CT scan if lung cancer 
screening was also included.
The mean burden/inconvenience and the mean worry 
for each of the four screening tests are given in Table 3. 
Both were measured on a scale from 1–5. There were 
significant differences between the screening tests in 
both burden/inconvenience and worry, with significantly 
higher values for ultrasound, blood test and low-dose CT 
than for urine test [mean difference 0.38 (0.32–0.44) and 
0.16 (0.12–0.19) for burden/inconvenience and worry 
respectively for ultrasound, 0.33 (0.28–0.37) and 0.11 
(0.07–0.15) for blood test and 0.69 (0.62–0.75) and 0.47 
(0.41–0.53) for low-dose CT]. Additionally, both bur-
den/inconvenience and worry were significantly higher 
for low-dose CT than ultrasound (mean difference 0.31 
(0.26–0.35) and 0.36 (0.31–0.41)).
Table 1 Participant characteristics
*ABC1 = higher SES, C2DE = lower SES
**On a scale of 3–15 where 3 = no worry, 15 = maximum worry
***On a scale of 1–100 from unlikely to likely
****Where high/low awareness was defined as above/below the median score. 
The breakdown for each risk factor/symptom can be found in Additional file 3: 
Supplementary Table 1, and the scoring system in Additional file 2
Participant characteristic n (%) or mean (± s.d.)
Age
 45–54 590 (57.7)
 55–64 328 (32.1)
 > 65 103 (10.1)
 Mean (± s.d.) 54.3 (± 7.1)
Sex (n, % female) 513 (50.2)
Country
 UK 668 (65.4)
 US 183 (17.9)
 Europe 77 (7.5)
University level education 471 (46.1)
Ethnicity (n, % White) 973 (95.3)
General health measure
 Excellent, very good, good 811 (79.4)
 Fair, poor 210 (20.6)
Smoking status
 Non‑smoker 512 (50.1)
 Ex‑smoker 345 (33.8)
 Current smoker 164 (16.1)
BMI (kg/m2) (mean ± s.d) 27.4 (± 5.7)
Previous diagnosis of cancer 63 (6.2)
Family history of kidney cancer 29 (2.8)
Social group*
 ABC1 778 (76.2)
 C2DE 188 (18.4)
Kidney cancer knowledge
 I am very familiar with it 6 (0.6)
 I have only heard of the term before 497 (48.7)
 I know a little about the disease 180 (17.6)
 Nothing at all 338 (33.1)
Cancer worry (mean ± s.d)** 5.6 (± 2.3)
Cancer risk perception (mean ± s.d)*** 34.1 (± 23.2)
Kidney cancer symptom awareness****
 High symptom awareness (≥ 5) 547 (53.6)
 Low symptom awareness (< 5) 474 (46.4)
Kidney cancer risk factor awareness****
 High risk factor awareness (≥ 43) 585 (57.3)
 Low risk factor awareness (< 43) 436 (42.7)
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After adjusting for participant characteristics (age, 
sex, education level, ethnicity, self-reported general 
health, country of residence, income group, BMI, smok-
ing status, prior history of cancer, family history of 
kidney cancer), cancer worry, perceived risk of cancer, 
beliefs about cancer outcomes and treatments, and the 
burden/inconvenience and worry associated with the 
tests, and clustering of response by participant, there 
were significant differences between the different tests 
in intention to take up screening (Fig. 2). In particular, 
compared with intention to take up screening with a 
urine test, participants were half as likely to report that 
they intended to undergo blood [OR 0.56 (0.43–0.73)] 
or ultrasound [OR 0.50 (0.38–0.67)] testing compared 
to urine testing, and half again as likely to report that 
they intended to take part in a screening programme 
featuring a low dose CT scan [OR 0.19 (0.14–0.27)).
Participants with higher BMI and higher general can-
cer worry were more likely to report intention to attend 
screening (Fig. 3). Being more worried about the screen-
ing tests or associating more burden and inconvenience 
were associated with decreased odds of intending to take 
up screening overall in the study population. There was, 
however, an interaction between general cancer worry 
and worry about the screening tests, with worry about 
screening tests associated with reduced odds of intend-
ing to attend only in those with low cancer worry (can-
cer worry scale ≤ 5) (OR 0.67 (0.48–0.94)) and not in 
than those with high cancer worry (OR 0.98 (0.69–1.40)). 
There was no evidence of an interaction (p>0.05) for the 
other potential interactions assessed. Although not sta-
tistically significant as a result of the small numbers with 
a family history of kidney cancer, having a family history 
of kidney was also associated with an increased odds of 
intending to take up screening (OR 4.70 (0.41–53.7), with 
Table 2 General cancer beliefs and attitudes towards kidney cancer screening
*Questions that were combined using published coefficients to form “Beliefs about cancer outcomes”
Strongly agree 
/agree (n, %)
Neither agree 
nor disagree 
(n, %)
Disagree 
or Strongly 
disagree (n, %)
General cancer beliefs
“These days, many people with cancer can expect to continue with normal activities and 
responsibilities”*
704 (69.0) 206 (20.2) 110 (10.9)
“Cancer can often be cured”* 740 (72.5) 199 (19.5) 82 (8.1)
“Some people think a diagnosis of cancer is a death sentence. To what extent do you agree or 
disagree that cancer is a death sentence?”*
138 (13.5) 310 (30.4) 573 (56.1)
Beliefs about cancer treatment: “Most cancer treatment is worse than the cancer itself” 406 (40.1) 343 (33.6) 272 (26.6)
Cancer fatalism: “I would NOT want to know if I have cancer” 68 (6.7) 109 (10.7) 844 (82.7)
Attitudes towards kidney cancer screening
“I would be so worried about what might be found at kidney cancer screening that I would 
prefer not to have it.”
72 (7.1) 83 (8.1) 866 (84.8)
“Kidney cancer screening is only necessary if I have symptom” 80 (7.8) 149 (14.6) 792 (77.6)
“I don’t think there is any point going for kidney cancer screening because it won’t affect the 
outcome”
13 (1.3) 71 (7) 937 (91.8)
“Kidney cancer screening could reduce my chance of dying from kidney cancer.” 937 (91.8) 45 (4.4) 39 (3.8)
Table 3 Intention to take up screening and the burden/inconvenience and worry associated with each screening test
*1=none and 5=very great; **10 participants did not answer this question.
Screening test Mean Burden/ inconvenience 
(mean ± sd)*
Worry (mean ± sd)* Intention to take up screening
Unlikely n (%) Likely n (%)
Urine test 1.2 (± 0.5) 1.2 (± 0.6) 60 (5.9) 961 (94.1)
Blood test 1.6 (± 0.7) 1.4 (± 0.7) 99 (9.7) 922 (90.3)
Ultrasound scan 1.6 (± 0.8) 1.3 (± 0.7) 107 (10.5) 914 (89.5)
Low dose CT scan 1.9 (± 0.9) 1.7 (± 0.9) 217 (21.3) 804 (78.8)
Low dose CT scan combined with 
lung screening**
– – 49 (4.8) 962 (94.2)
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27 of the 29 participants with a family history of kidney 
cancer likely to take up all four screening tests. These 
findings were similar when each screening option was 
considered separately (Additional file  3: Supplementary 
Table  2 and  Additional file  4: Supplementary  Fig.  1a-e). 
Notably all those with a family history of kidney cancer 
reported they would take up screening with an ultra-
sound scan, 28 out of 29 would take up screening with 
urine or blood testing, and 27 out of 29 would take up 
low-dose CT scanning.
The reported influence of other factors on intention to 
attend kidney cancer screening are reported in Table  4. 
Having symptoms of kidney cancer and a recommenda-
tion by their GP were the most influential factors.
Discussion
To the best of our knowledge, this study is the first to 
assess public attitudes towards potential kidney cancer 
screening programmes. Participants expressed high levels 
of intention to take-up kidney cancer screening, both 
within kidney cancer specific screening programmes 
and in conjunction with lung cancer screening. This was 
despite over 80% knowing nothing about kidney cancer 
or having only heard of the condition before participating 
in the survey. There were significant differences in inten-
tion between screening modalities, with a preference for 
urine testing or low-dose CT combined with lung cancer 
screening over a blood test, ultrasound scan or low-dose 
CT alone. Participants were also more likely to intend to 
undergo screening if they reported higher general cancer 
worry or less burden/inconvenience associated with the 
screening test, and if they had symptoms of kidney can-
cer or their GP had recommended screening. Less worry 
about the screening test was also associated with higher 
intention to attend, but only in those with lower gen-
eral cancer worry. For those with higher general cancer 
worry, the general worry about cancer appeared to domi-
nate any worry associated with the screening test itself.
Fig. 1 Participants expressing intention to take up screening across each of the five screening modalities. Blank areas indicate 0 participants. 
n=1021
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Fig. 2 Odds (OR ± 95% confidence intervals) of intending to take up screening with each of the five screening modalities, adjusting for participant 
characteristics, the burden/inconvenience and worry associated with each test, and clustering of response by participant. *significantly lower than 
urine test (p<0.05)
Fig. 3 The association between participant characteristics and intention to attend screening across all screening modalities. Odds ratios (OR) are 
adjusted for all factors in the figure. Cancer worry is measured on a scale from 3 to 15, perceived risk of cancer from 0 to 100, beliefs about cancer 
outcomes from 1.3 to 6.6, beliefs about cancer treatment from 1 to 5, burden/inconvenience and worry about the tests from 1 to 5.* p < 0.05
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Comparison with literature
The overall positive attitude towards a screening pro-
gramme for kidney cancer mirrors the general enthu-
siasm for cancer screening seen in population based 
surveys [20] and findings of a similar study on a potential 
lung cancer screening programme [13]. In that study over 
90% of survey respondents believed that there was ben-
efit to lung cancer screening, with the majority agreeing 
that lung screening could reduce chances of lung cancer 
death and only a small minority endorsing avoidance of 
lung cancer screening due to fear of what might be found 
or low perceived effectiveness of screening.
The observed differences between tests in intention to 
take part in a screening programme, with a preference for 
urine testing over a blood test, ultrasound scan or low-
dose CT alone, is also consistent with existing literature 
which reports a preference for non-invasive tests requir-
ing no preparation and causing no pain or long-term 
harm [21–23]. The greater intention seen for low-dose 
CT in combination with lung cancer screening likely 
reflects greater acceptability for combination screening, 
as seen in the context of a ‘One Stop’ cancer screening 
programme [24]. Given the low prevalence of kidney can-
cer, such a ‘bolt on’ screening programme may well be the 
most cost-effective as well as the most acceptable. It may 
also increase uptake of existing programmes [25].
Strengths and limitations
The survey was developed with the support of patient and 
public representatives in order to maximise participants’ 
understanding and, where possible, previously validated 
questions were used. The main limitation is our use of 
an online recruitment platform. Although the platform 
we used has been developed specifically for research 
and enabled us to rapidly recruit participants of differ-
ent ages and from different socio-economic backgrounds, 
compared with the UK and US population, the partici-
pants in this study were more likely to have university 
level education (46% in this study compared with 40% in 
the UK [26] and 35% in the US [27]) and be of White eth-
nicity (95% in this study compared with 86% in the UK 
[28] and 76% in the US [29]) and high socioeconomic 
status (76% in social group ABC1 in this study compared 
with 54% in England [30]). Uptake of other cancer screen-
ing programmes is known to be around 5–15% higher 
amongst these groups than those without university 
education, of ethnic minority groups and in lower social 
classes [31, 32]. The high proportion of participants 
expressing an intention to attend screening observed in 
this study may therefore be an over-estimation of inten-
tion in the wider population. Additionally, Prolific mem-
bers are experienced in completing online tasks and their 
views may not be representative of those of the general 
population [33]. However, while these differences might 
lead to over-estimation of levels of intention and affect 
the absolute levels of worry and burden reported by the 
respondents as a whole, the differences observed between 
screening tests and the associations between worry and 
burden and other participant socio-demographic char-
acteristics and intention to take up screening would be 
expected to be generalizable to other populations [34]. In 
the absence of an existing screening programme we were 
also only able to measure intention and not attendance at 
screening. Although there is an established relationship 
between screening intention and screening attendance 
[35], there is known to be an ‘intention-behaviour gap’ 
which is modified by various factors [36, 37]. The actual 
uptake of any future screening programme is therefore 
likely to be lower than the estimates of intention in this 
study. The uptake of any future screening programme 
will also likely depend on the information provided to 
eligible individuals. As data are currently not available 
Table 4. Factors influencing intention to take up screening
Influence on intention to take up screening
Much/slightly less likely (n, %) No influence (n, %) Much/slightly 
more likely 
(n, %)
If it was recommended by my GP? 11 (1.1) 129 (12.6) 881 (86.3)
If I had symptoms of kidney cancer? 13 (1.3) 45 (4.4) 963 (94.3)
If I could do the test at home? 26 (2.5) 277 (27.1) 718 (70.3)
If I could do the test at the GP? 20 (2) 278 (27.2) 723 (70.8)
If I had to go to the hospital for the test? 244 (23.9) 377 (36.9) 400 (39.2)
If I could make an appointment at the weekend or in the 
evenings?
28 (2.7) 465 (45.5) 528 (51.7)
If I had to leave work early? 179 (17.5) 657 (64.3) 185 (18.1)
If I could book the appointment online? 19 (1.9) 449 (44) 553 (54.2)
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on all the potential benefits and harms of kidney cancer 
screening, the information provided to participants in 
this study was based on estimates from the best available 
evidence and provided in less detail that would likely be 
included in any future screening programme. In particu-
lar, although we mentioned the possibility of both false 
positive and false negative findings as a result of screen-
ing, we did not provide participants with specific details 
on the possibility of detecting benign small renal masses 
or data on the growth rate of small incidentally detected 
tumours. With on-going research in this area, especially 
surrounding potential blood and urine biomarkers and 
approaches to the management of small renal masses, 
these estimates may change, making screening either 
more or less favourable to individuals.
Conclusion
Among the participants in our study, we found that there 
is an overall enthusiasm for kidney cancer screening, 
with high potential uptake rates. Our findings also high-
light the influence of screening modality, with particular 
support for urine and low-dose CT combined with lung 
cancer screening, as well as individual-level and system-
level factors that are likely to influence uptake. Together 
these findings support on-going research into kidney 
cancer screening tests and the potential for combining 
kidney cancer screening with existing or new screening 
programmes.
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